维普中文期刊产品整合服务
14篇 您的检索式:作者名="Parruti"
    题名 作者 年代 出处 被引量
1CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis显示文摘AIM: To determine intra-hepatic blood flow and liver stiffness in patients with non-alcoholic fatty liver disease(NAFLD) and non-alcoholic steatohepatitis (NASH) using contrast-enhanced ultrasound and fibroscan.METHODS: This prospective study included 15 patients with NAFLD, 17 patients with NASH and 16 healthy controls.In each patient, real-time ultrasound was used to locate the portal vein (PV) and the right liver lobe, and 5 mL of SonoVue? was then injected intravenous in a peripheral vein of the left arm over a 4-s span. Digital recording was performed for 3 min thereafter. The recording was subsequently retrieved to identify an area of interest in the PV area and in the right liver parenchyma(LP) to assess the blood flow by processing the data using dedicated software (Qontrast?, Bracco, Italy).The following parameters were evaluated: percentage of maximal contrast activity (Peak%), time to peak (TTP, s), regional blood volume (RBV, cm3), regional blood flow (RBF, cm3/s) and mean transit time (MTT, s).At 24-48 h post-injection, liver stiffness was evaluated using Fibroscan and measured in kPa. The statistical evaluation was performed using Student’s t test.RESULTS: In the PV, the Peak%, RBV and RBF were significantly reduced in the NAFLD and NASH patientscompared with the controls (Peak%: NAFLD 26.3 ± 6.6,NASH 28.1 ± 7.3 vs controls 55.8 ± 9.9, P < 0.001;RBV: NAFLD 4202.3 ± 3519.7, NASH 3929.8 ± 1941.3vs controls 7473 ± 3281, P < 0.01; RBF: NAFLD 32.5± 10.8, NASH 32.7 ± 12.1 vs controls 73.1 ± 13.9, P< 0.001). The TTP in the PV was longer in both patient groups but reached statistical significance only in the NASH patients compared with the controls (NASH 79.5± 37.8 vs controls 43.2 ± 30, P < 0.01). In the LP,the Peak%, RBV and RBF were significantly reduced in the NAFLD and NASH patients compared with the controls (Peak%: NAFLD 43.2 ± 7.3, NASH 41.7 ± 7.7 vs controls 56.6 ± 6.3, P < 0.001; RBV: NAFLD 4851.5± 2009, NASH 5069.4 ± 2292.5 vs controls 6922.9 ±2461.5, P < 0.05; RBF: NAFLD 55.7 ± 10.1, NASH 54.5 ± 12.1 vs controls 75.9 ± 10.5, P < 0.001). The TTP was longer in both patient groups but did not reach statistical significance. The MTT in both the PV and LP in the NAFLD and NASH patients was not different from that in the controls. Liver stiffness was significantly increased relative to the controls only in the NASH patients(NASH: 6.4 ± 2.2 vs controls 4.6 ± 1.5, P < 0.05).CONCLUSION: Blood flow derangement within the liver present not only in NASH but also in NAFLD suggests that a vascular flow alteration precedes liver fibrosis development.Sila Cocciolillo Giustino Parruti Leonardo Marzio 2014World Journal of Hepatology2014,6,7:7
2Long- term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse显示文摘MANZOLI L PARRUTI G TORO P M 2006AIDS Patient Care STDS2006,20,1:1
3Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy:a case-control study of the outcome in children显示文摘Nigro G Adler SP Parruti G 2012J Infect Dis2012,205,:1
4Preliminary evaluation of the safety and efficacy of standard intravenous immunoglobulins in pregnant women with primary cytomegalovirus infection显示文摘Polilli E Parruti G D'Arcangelo F 2012Clin Vaccine Immunol2012,19,:1
5Genetic and physical map of the yon Recklinghausen nenrofibromatosis ( NF1 ) region on chromosome 17显示文摘Yagle MK Parruti G Xu W 1990Proc Natl Acad Sci U S A1990,87,18:1
6Genetic and physical map of the yon Recklinghausen neurofibromatosis region on chromosome 17显示文摘Yagle MK Parruti G Xu w 0,,:1
7Immunoglobulin therapyof fetal cytomegalovirus infection occurring in the first half of pregnancy-a case-control study of the outcome in children 显示文摘Nigro G Adler S P Parruti G 2012J Infect Dis2012,205,2:1
8Genetic and physical map of the von Recklinghausen neurofibromatosis ( NF1 ) region on chromosome 17显示文摘 Parruti G Xu W 1990Proc Natl Acad Sci USA1990,87,18:1
9Genetic and physical map of the yon recklinghausen neurofibromatosis (NF1) region on chro- mosome 17显示文摘Yaqle MK Parruti G Xu W 1990Proe Natl Aead Sei USA1990,87,18:1
10Genetic and physical map of the yon Recklinghausen neurofibromatosis (NF1) region on chromosome 17显示文摘Yagle MK Parruti G Xu W 1990Proc Natl Acad Sci USA1990,87,18:1
11Genetic and physical map of the yon Recklinghausen neurofibromatosis (NF1) region on chromosome 17显示文摘Yagle MK Parruti G Xu W 1990Proc Natl Acad Sci USA1990,7,18:1
12Genetic and physical map of the von Recklinghausen neurofibromatosis (NF1) region on chromosome 17显示文摘Yagle MK Parruti G Xu W 1990Proc Natl Acad Sci USA1990,7,18:1
13Molecular analysis of human β-arrestin-l : cloning, tissue , distribution, and regulation of expres- sion 显示文摘Parruti G Peracchia F Sallese M 1993J Biol Chem1993,268,13:1
14Prelimi- nary evaluation of the safety and efficacy of standardintravenous immunoglobulins in pregnant women with primary cytomegalovirus infection显示文摘Polilli E1 Parruti G D'Arcangelo F 2012Clin Vac- cine Immunol2012,19,12:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费